End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
26 USD | -3.56% |
|
+21.13% | +150.00% |
06-12 | Dianthus Therapeutics Secures US FDA Approval to Launch Phase 2 Study of DNTH103 in Multifocal Motor Neuropathy | MT |
06-12 | Dianthus Therapeutics Gets FDA Clearance for DNTH103 Phase 2 Trial | DJ |
Sales 2024 * | 1.78M 141M | Sales 2025 * | 2M 158M | Capitalization | 741M 58.52B |
---|---|---|---|---|---|
Net income 2024 * | -63M -4.97B | Net income 2025 * | -88M -6.95B | EV / Sales 2024 * | 240 x |
Net cash position 2024 * | 314M 24.74B | Net cash position 2025 * | 518M 40.92B | EV / Sales 2025 * | 111 x |
P/E ratio 2024 * |
-11.7
x | P/E ratio 2025 * |
-9.94
x | Employees | 53 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.16% |
1 day | -3.56% | ||
1 week | +21.13% | ||
Current month | +20.31% | ||
1 month | +1.44% | ||
3 months | -7.31% | ||
6 months | +259.61% | ||
Current year | +150.00% |
![Extreme 24.15](/images/extremecours_fleche.png)
![Extreme 19.845](/images/extremecours_fleche.png)
![Extreme 10.22](/images/extremecours_fleche.png)
![Extreme 6.58](/images/extremecours_fleche.png)
![Extreme 6.58](/images/extremecours_fleche.png)
![Extreme 6.58](/images/extremecours_fleche.png)
![Extreme 6.58](/images/extremecours_fleche.png)
Date | Price | Change | Volume |
---|---|---|---|
17/06/24 | 25.26 | -2.85% | 413,582 |
14/06/24 | 26 | -3.56% | 272,224 |
13/06/24 | 26.96 | +7.15% | 199,050 |
12/06/24 | 25.16 | +5.01% | 204,084 |
11/06/24 | 23.96 | +11.62% | 180,624 |
End-of-day quote Nasdaq, June 13, 2024
More quotes![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+150.00% | 741M | |
+16.42% | 122B | |
+19.02% | 113B | |
+3.14% | 22.66B | |
-16.20% | 21.34B | |
-39.57% | 16.92B | |
-11.63% | 16.68B | |
-16.24% | 16.61B | |
+2.68% | 13.62B | |
+21.16% | 11.04B |
- Stock Market
- Equities
- DNTH Stock